research Sacituzumab Govitecan-Hziy (Trodelvy™)
Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
Search
for
Sort by
Research
90-120 / 1000+ results
research 257 Is EBF1 a negative regulator of WNT10A in the development of androgenetic alopecia?
Finasteride helps female-pattern hair loss.
research 083 The effect of topical hair growth promoters on internal calcium of human outer root sheath cells(ORSCs)
research Abstracts Pt.21
research DEVELOPING AND VALIDATING AN HPLC METHOD TO QUANTIFY SIMULTANEOUSLY DUTASTERIDE AND THEIR RELATED MOLECULES (DUTASTERIDE ACID, 2,5 BIS- (TRI FLUORO METHYL)-ANILINE AND DUTASTERIDE 17 α-EPIMER) IN CAPSULES
A reliable method was created to measure dutasteride and related molecules in capsules.
research 573 Discovery of JW0061, a novel GFRA1 agonist, as a hair regeneration stimulant via WNT signaling activation in dermal papilla cells
JW0061 may be a new treatment for hair loss by promoting hair growth through WNT signaling.
research Tamoxifen-induced androgenetic alopecia in a dialysis patient with sclerosing encapsulating peritonitis (SEP)
research Fluxactive Complete (#1 PREMIUM PROSTATE SUPPORT FORMULA) Managing Prostate Wellness And Bladder Functions!
research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
CG2001 is safe and well-tolerated for treating hair loss in men.
research Tebentafusp-tebn (Kimmtra®)
Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
research MICROBIAL OXIDATION OF FINASTERIDE WITH MACROPHOMINA PHASEOLINA(KUCC 730)
research ISID1116 – Novel androgen receptor degrader for androgenetic alopecia (AGA) application
research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
CG2001 is safe, well-tolerated, and a promising treatment for hair loss with fewer side effects.
![Discovery of 7-Methoxy-6-[4-(4-Methyl-1,3-Thiazol-2-yl)-1H-Imidazol-5-yl]-1,3-Benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia](/images/research/9620bd26-3366-4f2a-bcac-f511697bbc41/small/35997.jpg)
research Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1<i>H</i>-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia
A new compound shows promise as a topical treatment for hair loss.
research “Finasteride”
research FORMULATION OF TOPICAL FINASTERIDE AND EVALUATION OF ITS PERCUTANEOUS ABSORPTION
research A double blind, randomised, vehicle-controlled, safety and tolerance study of topical PSK 3841 solution at 5% administered twice daily over four weeks to healthy Caucasian males with androgenetic alopecia
research Compatibility of Different Formulations in TrichoConceptTM Vehicles for Hair Treatments
Different hair loss treatment ingredients work well with TrichoTech™ vehicles for 3 to 6 months, making them good for use in hair treatments.